Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We hope you are finding ways to cope during these trying times and are taking the long view. As the sages say: This, too, shall pass. Of course, they never say when, exactly. But this is why the word “optimistic” was invented. On that note, the time has come to fire up the coffee kettle and dig in for another busy day. So here are a few items of interest to help you along. Keep busy. Keep healthy. Keep in touch.

A new multiple sclerosis drug from Bristol Myers Squibb (BMY) was approved by the Food and Drug Administration — a decision that may help Bristol shareholders before patients, STAT explains. The once-daily pill, to be sold under the brand name Zeposia, enters a multiple sclerosis treatment market crowded with entrenched rival medicines. But with people at risk of coronavirus infections and the health care system struggling, Bristol says the “responsible course of action” is to delay a formal commercial launch until the crisis subsides.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.